Difference between revisions of "Brigatinib (Alunbrig)"
m |
m |
||
| Line 13: | Line 13: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2017-04-28: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555841.htm Accelerated approval] for the treatment of patients with metastatic [[Biomarkers#ALK|anaplastic lymphoma kinase (ALK)]]-[[Biomarkers#Rearrangement|positive]] [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]] who have progressed on or are intolerant to [[Crizotinib (Xalkori)|crizotinib]]. ''(Based on [https://clinicaltrials.gov/ct2/show/NCT02094573 ALTA])'' |
| − | * | + | *2020-05-22: Approved for adult patients with [[Biomarkers#ALK|anaplastic lymphoma kinase (ALK)]]-[[Biomarkers#Rearrangement|positive]] metastatic [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]]. ''(Converted to regular approval and prior treatment requirement removed); based on [https://clinicaltrials.gov/ct2/show/NCT02737501 ALTA-1L])'' |
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| − | *11 | + | *2018-11-22: Initial authorization |
| + | ==History of changes in Health Canada indication== | ||
| + | *2018-07-26: Initial notice of compliance with conditions | ||
| + | *2022-07-20: Conditions were met | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' AP26113 | *'''Code name:''' AP26113 | ||
| Line 38: | Line 41: | ||
[[Category:FDA approved in 2017]] | [[Category:FDA approved in 2017]] | ||
[[Category:EMA approved in 2017]] | [[Category:EMA approved in 2017]] | ||
| + | [[Category:Health Canada approved in 2018]] | ||
Revision as of 13:26, 29 March 2023
General information
Class/mechanism: Tyrosine kinase inhibitor (TKI); inhibits multiple kinases including anaplastic lymphoma kinase (ALK), ROS1, insulin-like growth factor-1 receptor (IGF-1R), FLT-3, and EGFR deletion and point mutations. Brigatinib inhibited growth of cells with EML4-ALK and NPM-ALK fusion proteins. Brigatinib prevents autophosphorylation of ALK and, subsequently, downstream signaling through STAT3, AKT, ERK1/2, and S6. Brigatinib inhibited cells expressing EML4-ALK, as well as mutant forms of EML4-ALK, such as as G1202R and L1196M. Brigatinib was able to inhibit some mutant forms which are associated with resistance to ALK inhibitors including crizotinib, as well as EGFR-Del (E746-A750), ROS1-L2026M, FLT3-F691L, and FLT3-D835Y. [1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 2017-04-28: Accelerated approval for the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. (Based on ALTA)
- 2020-05-22: Approved for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). (Converted to regular approval and prior treatment requirement removed); based on ALTA-1L)
History of changes in EMA indication
- 2018-11-22: Initial authorization
History of changes in Health Canada indication
- 2018-07-26: Initial notice of compliance with conditions
- 2022-07-20: Conditions were met
Also known as
- Code name: AP26113
- Brand names: Alunbrig, Biganib, Briganix, Trepmac